ING Group’s Ionis Pharmaceuticals IONS Stock Holding History

ING Group’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-8,394	Closed	-$363K	–	668
2014 Q1	$363K	Buy	+8,394	New	+$407K	﹤0.01%	623

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ING Group's IONS Position: Q2 2014 in Review

ING Group sold out of Ionis Pharmaceuticals (IONS) in Q2 2014, closing a stake of 8,394 shares — an estimated $363K sold.

ING Group first reported a position in IONS in Q1 2014 and held it in 1 quarter. The position peaked at $363K in Q1 2014. 238 funds tracked by Wall St. Rank hold IONS as of Q2 2014.

ING Group reported no remaining Ionis Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
ING Group sold 8,394 Ionis Pharmaceuticals shares in Q2 2014, an estimated $363K.
ING Group first reported a position in Ionis Pharmaceuticals in Q1 2014 and held it in 1 quarter.
ING Group's Ionis Pharmaceuticals position peaked at $363K in Q1 2014.
238 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2014.

Based on ING Group's 13F filing for Q2 2014, filed 14 Aug 2014.